Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
Investor's Business Daily on MSN1d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
In other Roivant Sciences news, CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05 ...
NASDAQ ROIV opened at $10.66 on Monday. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market capitalization of $7.61 billion, a price-to ...
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback